Differential effects of dexmedetomidine on Gram-positive and Gram-negative bacterial killing and phagocytosis
Issued Date
2023-07-01
Resource Type
ISSN
15675769
eISSN
18781705
Scopus ID
2-s2.0-85159483102
Journal Title
International Immunopharmacology
Volume
120
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Immunopharmacology Vol.120 (2023)
Suggested Citation
Maisat W., Han X., Koutsogiannaki S., Soriano S.G., Yuki K. Differential effects of dexmedetomidine on Gram-positive and Gram-negative bacterial killing and phagocytosis. International Immunopharmacology Vol.120 (2023). doi:10.1016/j.intimp.2023.110327 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/82856
Title
Differential effects of dexmedetomidine on Gram-positive and Gram-negative bacterial killing and phagocytosis
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Dexmedetomidine is a commonly used sedative in perioperative and intensive care settings with purported immunomodulatory properties. Since its effects on immune functions against infections have not been extensively studied, we tested the effects of dexmedetomidine on Gram-positive [Staphylococcus aureus and Enterococcus faecalis] and Gram-negative bacteria [Escherichia coli], and on effector functions of human monocytes THP-1 cells against them. We evaluated phagocytosis, reactive oxygen species (ROS) formation, and CD11b activation, and performed RNA sequencing analyses. Our study revealed that dexmedetomidine improved Gram-positive but mitigated Gram-negative bacterial phagocytosis and killing in THP-1 cells. The attenuation of Toll-like receptor 4 (TLR4) signaling by dexmedetomidine was previously reported. Thus, we tested TLR4 inhibitor TAK242. Similar to dexmedetomidine, TAK242 reduced E. coli phagocytosis but enhanced CD11b activation. The reduced TLR4 response potentially increases CD11b activation and ROS generation and subsequently enhances Gram-positive bacterial killing. Conversely, dexmedetomidine may inhibit the TLR4-signaling pathway and mitigate the alternative phagocytosis pathway induced by TLR4 activation through LPS-mediated Gram-negative bacteria, resulting in worsened bacterial loads. We also examined another α2 adrenergic agonist, xylazine. Because xylazine did not affect bacterial clearance, we proposed that dexmedetomidine may have an off-target effect on bacterial killing process, potentially involving crosstalk between CD11b and TLR4. Despite its potential to attenuate inflammation, we provide a novel insight into potential risks of dexmedetomidine use during Gram-negative infections, highlighting the differential effect of dexmedetomidine on Gram-positive and Gram-negative bacteria.